Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy?

J Dermatol. 2021 Feb;48(2):e80-e81. doi: 10.1111/1346-8138.15621. Epub 2020 Nov 7.

Authors

Karam Khaddour¹, Ilana S Rosman^{2

3}, Farrokh Dehdashti⁴, George Ansstas¹

Affiliations

¹ Division of Medical Oncology, Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA.
² Division of Dermatology, Washington University in St Louis, St Louis, Missouri, USA.
³ Department of Pathology and Immunology, Washington University in St Louis, St Louis, Missouri, USA.
⁴ Division of Nuclear Medicine, Department of Radiology, Washington University in St Louis, St Louis, Missouri, USA.

PMID: 33161593
DOI: 10.1111/1346-8138.15621

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Carcinoma, Merkel Cell* / drug therapy
Humans
Immunotherapy
Ipilimumab
Nivolumab
Skin Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Ipilimumab
Nivolumab
avelumab